Literature DB >> 19356036

Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.

Punam Sandhu1, Paul A Andrews, Maribeth P Baker, Kenneth A Koeplinger, Eric D Soli, Thomas Miller, Thomas A Baillie.   

Abstract

The disposition of vorinostat, an anticancer agent, was investigated in rats and dogs. Vorinostat possessed high serum clearance, a short elimination half-life and low oral bioavailability in both species. The renal route played an important role in the elimination of drug-related material and vorinostat was eliminated primarily by metabolic biotransformation.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 19356036     DOI： 10.2174/187231207780363642

Source DB:  PubMed          Journal:  Drug Metab Lett        ISSN： 1872-3128


  7 in total

1.  Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine.

Authors:  Elham A Mohamed; Yunqi Zhao; Mahasen M Meshali; Connie M Remsberg; Thanaa M Borg; Abdel Monem M Foda; Jody K Takemoto; Casey L Sayre; Stephanie E Martinez; Neal M Davies; M Laird Forrest
Journal:  J Pharm Sci       Date:  2012-07-17       Impact factor: 3.534

2.  Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells.

Authors:  Tuan Hiep Tran; Thiruganesh Ramasamy; Duy Hieu Truong; Beom Soo Shin; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Pharm Res       Date:  2014-02-22       Impact factor: 4.200

3.  Normalization of Hepatic Homeostasis in the Npc1nmf164 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat.

Authors:  Andrew B Munkacsi; Natalie Hammond; Remy T Schneider; Dinindu S Senanayake; Katsumi Higaki; Kirill Lagutin; Stephen J Bloor; Daniel S Ory; Robert A Maue; Fannie W Chen; Antonio Hernandez-Ono; Nicole Dahlson; Joyce J Repa; Henry N Ginsberg; Yiannis A Ioannou; Stephen L Sturley
Journal:  J Biol Chem       Date:  2016-12-28       Impact factor: 5.157

Review 4.  HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer.

Authors:  Cristina Maccallini; Alessandra Ammazzalorso; Barbara De Filippis; Marialuigia Fantacuzzi; Letizia Giampietro; Rosa Amoroso
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-26

5.  Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

Authors:  S J McDonnel; L A Tell; B G Murphy
Journal:  J Vet Pharmacol Ther       Date:  2013-11-18       Impact factor: 1.786

6.  Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach.

Authors:  Silvia Da Ros; Luca Aresu; Serena Ferraresso; Eleonora Zorzan; Eugenio Gaudio; Francesco Bertoni; Mauro Dacasto; Mery Giantin
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

7.  Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.

Authors:  Yu-Bo Zhou; Yang-Ming Zhang; Hong-Hui Huang; Li-Jing Shen; Xiao-Feng Han; Xiao-Bei Hu; Song-da Yu; An-Hui Gao; Li Sheng; Ming-Bo Su; Xiao-Li Wei; Yue Zhang; Yi-Fan Zhang; Zhi-Wei Gao; Xiao-Yan Chen; Fa-Jun Nan; Jia Li; Jian Hou
Journal:  Acta Pharmacol Sin       Date:  2021-08-02       Impact factor: 6.150
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.